Clark Capital Management Group’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$35.9M Sell
615,727
-1,047,276
-63% -$61.8M 0.22% 126
2026
Q2
$93.2M Buy
1,663,003
+23,035
+1% +$1.2M 0.51% 48
2026
Q1
$78.7M Sell
1,639,968
-113,842
-6% -$4.99M 0.49% 53
2025
Q4
$67.8M Buy
1,753,810
+1,968
+0.1% +$75K 0.42% 78
2025
Q3
$61.8M Buy
+1,751,842
New +$63.4M 0.39% 97

Other funds holding RPRX

Clark Capital Management Group's RPRX Position: Q3 2026 in Review

Clark Capital Management Group reduced its Royalty Pharma (RPRX) stake by 63% in Q3 2026, selling an estimated $61.8M and leaving 615,727 shares worth $35.9M. The position accounts for 0.22% of the portfolio, ranked #126.

Clark Capital Management Group first reported a position in RPRX in Q3 2025 and has held it in 5 quarters since. The position peaked at $93.2M in Q2 2026. 705 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Clark Capital Management Group held 615,727 shares of Royalty Pharma worth $35.9M as of Q3 2026.
  • Clark Capital Management Group sold 1,047,276 Royalty Pharma shares in Q3 2026, an estimated $61.8M.
  • Royalty Pharma made up 0.22% of Clark Capital Management Group's portfolio in Q3 2026, its #126 holding.
  • Clark Capital Management Group first reported a position in Royalty Pharma in Q3 2025 and has held it in 5 quarters since.
  • Clark Capital Management Group's Royalty Pharma position peaked at $93.2M in Q2 2026.
  • 705 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Clark Capital Management Group's 13F filing for Q3 2026, filed 16 Nov 2026.